Structure of Geldanamycin
Western blot analysis of extracts from HEK293 cells, untreated or treated with indicated concentrations of Geldanamycin for 20 hours, using IKKα Antibody #2682 showing IKKα degradation (upper). β-Actin Antibody #4967 was used as a loading control (lower).
Geldanamycin is supplied as 600 μg powder. Store at or below -20ºC. Before usage, dissolve the chemical in 1.08 ml DMSO to make 1 mM Geldanamycin. For working concentrations of 300 nM-1 μM, dilute 1:3000 to 1:1000. Treat cells with the desired concentration for 20-48 hours. Store liquid form at or below -20ºC.
Store lyophilized or in solution at -20ºC, desiccated. Protect from light. In lyophilized form, the chemical is stable for 24 months. Once in solution, use within 1 week to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
|Molecular Weight||560.64 g/mol|
|Solubility||Soluble in DMSO at 10mg/ml.|
Geldanamycin (GA) is a naturally existing HSP90 inhibitor that belongs to the benzoquinone ansamycin family. GA binds to the amino terminal ATP-binding pocket of HSP90 and inhibits ATP binding and hydrolysis. HSP90 is a chaperone interacting with a wide variety of important target proteins for cell signaling and regulation during tumorgenesis (1,2). The binding of GA to HSP90 interferes with HSP-mediated target protein folding, leading to target aggregation and degradation (1-3). GA and its synthetic derivatives show higher affinity to HSP90 in tumor cells as compared to normal tissues and constitute a class of protential antitumor drugs (2-3).
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST's products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST's Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.